NCT06177665

Brief Summary

In this study, the investigators compared ultrasound-guided erector spinae plane (ESP) block and rhomboid intercostal block (RIB) on postoperative analgesic effect in unilateral breast surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P50-P75 for not_applicable postoperative-pain

Timeline
Completed

Started Jul 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2023

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 11, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 20, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

October 1, 2025

Status Verified

July 1, 2024

Enrollment Period

9 months

First QC Date

December 11, 2023

Last Update Submit

September 25, 2025

Conditions

Keywords

Regional AnesthesiaErector Spinae Plane BlockRhomboid Intercostal BlockBreast Surgery

Outcome Measures

Primary Outcomes (1)

  • Morphin Consumption

    Patients in both groups will provide with intravenous patient-controlled analgesia device containing morphine for postoperative analgesia

    during postoperative 24 hours

Secondary Outcomes (1)

  • Numerical Rating Scale(NRS)

    during postoperative 24 hours

Study Arms (2)

Erector Spinae Plane Block

EXPERIMENTAL

Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.

Other: Erector Spinae Plane Block

Rhomboid Intercostal Block

EXPERIMENTAL

Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.

Other: Rhomboid Intercostal Block

Interventions

Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.

Erector Spinae Plane Block

Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.

Rhomboid Intercostal Block

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who will undergo unilateral breast-conserving surgery (BCS) or modified radical mastectomy (MRM) with or without axillary lymph node dissection
  • Patients undergoing elective surgery
  • ASA (American Society of Anesthesiologists) physical status classification I-III

You may not qualify if:

  • Use of anticoagulants
  • Allergy to the medications to be used
  • Patients who use analgesic drugs due to a history of chronic pain
  • ASA (American Society of Anesthesiologists) physical status classification IV-V
  • Patients with psychiatric disorders
  • Presence of infection in the area where the block will be applied
  • Presence of deformity in the patient's spinal, paraspinal and area where the block will be applied
  • The patient does not accept the block application or cannot cooperate with the patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kocaeli University

Kocaeli, Turkey (Türkiye)

Location

Related Links

MeSH Terms

Conditions

Pain, PostoperativeAgnosia

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Study Officials

  • Sevim Cesur Okan

    Kocaeli University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

December 11, 2023

First Posted

December 20, 2023

Study Start

July 1, 2023

Primary Completion

March 30, 2024

Study Completion

June 1, 2024

Last Updated

October 1, 2025

Record last verified: 2024-07

Locations